Traci McCarty | Group VP, IR |
Jean-Jacques Bienaime | Chairman & CEO |
Jeffrey Ajer | Chief Commercial Officer |
Henry Fuchs | President, Worldwide Research & Development |
Brian Mueller | CFO & EVP |
Salveen Richter | Goldman Sachs Group |
Geoffrey Meacham | Bank of America Merrill Lynch |
Christopher Raymond | Piper Sandler & Co. |
Timothy Lugo | William Blair & Company |
Robyn Karnauskas | Truist Securities |
Joori Park | SVB Securities |
Paul Matteis | Stifel, Nicolaus & Company |
Akash Tewari | Jefferies |
Philip Nadeau | TD Cowen |
Jessica Fye | JPMorgan Chase & Co. |
Gena Wang | Barclays Bank |
Welcome to the BioMarin Pharmaceuticals First Quarter Investor Update Call. Hosting the conference call today from BioMarin is Traci McCarty, Group Vice President, Investor Relations. Please go ahead, Traci.
Thank you, Ross, and thank you all for joining us today. To remind you, this nonconfidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical, including expectations regarding BioMarin's financial performance, commercial products and potential future products in different areas of therapeutic research and development.